To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan

A Multicentre, Non-interventional Post Marketing Study of Safety and Efficacy of NovoEight® (rFVIII) During Long-Term Treatment of Haemophilia A in Japan

This study is conducted in Asia. The aim of this study is to evaluate the safety and efficacy of NovoEight® (recombinant factor VIII) in patients with haemophilia A in Japan in the setting of routine clinical practice.

Inclusion Criteria:

• Informed consent obtained before any study-related activities. Study-related activities are any procedure related to recording of data according to the protocol
• Male and female patients with the diagnosis of haemophilia A
• Age range is 0 year and above
• A decision to initiate treatment with commercially available NovoEight® has been made by the patient/parent and the physician

Exclusion Criteria:

• Known or suspected allergy to study product(s) or related products
• Previous participation in this study. Participation is defined as informed consent obtained
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation